PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Luye Pharma Group Ltd (2186.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINBMG570071099
SectorHealthcare
IndustryDrug Manufacturers—General

Highlights

Market CapHK$9.82B
PE Ratio17.40
Revenue (TTM)HK$6.14B
Gross Profit (TTM)HK$3.40B
EBITDA (TTM)HK$1.52B
Year RangeHK$2.34 - HK$4.03
Target PriceHK$3.08

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Luye Pharma Group Ltd

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Luye Pharma Group Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%NovemberDecember2024FebruaryMarchApril
-21.98%
22.14%
2186.HK (Luye Pharma Group Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Luye Pharma Group Ltd had a return of -27.61% year-to-date (YTD) and -30.23% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-27.61%5.84%
1 month-4.93%-2.98%
6 months-21.97%22.02%
1 year-30.23%24.47%
5 years (annualized)-17.34%11.44%
10 years (annualized)N/A10.46%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-29.49%9.89%-5.54%
202321.88%7.98%2.90%-4.36%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 2186.HK is 14, indicating that it is in the bottom 14% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of 2186.HK is 1414
Luye Pharma Group Ltd(2186.HK)
The Sharpe Ratio Rank of 2186.HK is 1212Sharpe Ratio Rank
The Sortino Ratio Rank of 2186.HK is 1515Sortino Ratio Rank
The Omega Ratio Rank of 2186.HK is 1616Omega Ratio Rank
The Calmar Ratio Rank of 2186.HK is 2525Calmar Ratio Rank
The Martin Ratio Rank of 2186.HK is 44Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Luye Pharma Group Ltd (2186.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


2186.HK
Sharpe ratio
The chart of Sharpe ratio for 2186.HK, currently valued at -0.77, compared to the broader market-2.00-1.000.001.002.003.004.00-0.77
Sortino ratio
The chart of Sortino ratio for 2186.HK, currently valued at -0.97, compared to the broader market-4.00-2.000.002.004.006.00-0.97
Omega ratio
The chart of Omega ratio for 2186.HK, currently valued at 0.88, compared to the broader market0.501.001.500.88
Calmar ratio
The chart of Calmar ratio for 2186.HK, currently valued at -0.40, compared to the broader market0.002.004.006.00-0.40
Martin ratio
The chart of Martin ratio for 2186.HK, currently valued at -1.62, compared to the broader market0.0010.0020.0030.00-1.62
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.05, compared to the broader market-2.00-1.000.001.002.003.004.002.05
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.98, compared to the broader market-4.00-2.000.002.004.006.002.98
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.501.001.501.36
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.55, compared to the broader market0.002.004.006.001.55
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.05, compared to the broader market0.0010.0020.0030.008.05

Sharpe Ratio

The current Luye Pharma Group Ltd Sharpe ratio is -0.77. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.77
2.03
2186.HK (Luye Pharma Group Ltd)
Benchmark (^GSPC)

Dividends

Dividend History

Luye Pharma Group Ltd granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to HK$0.00 per share.


PeriodTTM20232022202120202019201820172016
DividendHK$0.00HK$0.00HK$0.00HK$0.00HK$0.06HK$0.13HK$0.11HK$0.07HK$0.04

Dividend yield

0.00%0.00%0.00%0.00%1.66%2.26%1.93%1.17%0.80%

Monthly Dividends

The table displays the monthly dividend distributions for Luye Pharma Group Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2024HK$0.00HK$0.00HK$0.00
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2020HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.06HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2019HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.07HK$0.00HK$0.00HK$0.07HK$0.00HK$0.00HK$0.00
2018HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.05HK$0.00HK$0.00HK$0.05HK$0.00HK$0.00HK$0.00
2017HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.04HK$0.00HK$0.00HK$0.00HK$0.03HK$0.00HK$0.00
2016HK$0.04HK$0.00HK$0.00

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-74.15%
-3.90%
2186.HK (Luye Pharma Group Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Luye Pharma Group Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Luye Pharma Group Ltd was 81.72%, occurring on Oct 31, 2022. The portfolio has not yet recovered.

The current Luye Pharma Group Ltd drawdown is 74.15%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-81.72%Oct 31, 20141970Oct 31, 2022
-6.9%Sep 22, 201411Oct 8, 201415Oct 29, 201426
-5.72%Jul 23, 20146Jul 30, 20144Aug 5, 201410
-3.2%Aug 6, 20142Aug 7, 201411Aug 22, 201413
-2.93%Sep 3, 20142Sep 4, 20143Sep 10, 20145

Volatility

Volatility Chart

The current Luye Pharma Group Ltd volatility is 12.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%NovemberDecember2024FebruaryMarchApril
12.62%
3.64%
2186.HK (Luye Pharma Group Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Luye Pharma Group Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items